
ADC Therapeutics completes enrollment for ZYNLONTA combination trial
ADC Therapeutics has finished enrolling 100 patients for its LOTIS-7 Phase 1b trial, which tests the combination of ZYNLONTA and the bispecific antibody glofitamab in treating relapsed or refractory diffuse large B-cell lymphoma. The company plans to release full clinical data from the study by the end of 2026.























